SIX · UBSG.SW
UBS Group AG
CHF 39.71+CHF 1.11 (+2.88%)
UBS Group AG’s quoted price sits in the upper half of its reported 52-week range, 11.83% below the high.
Loading market information…
SIX · EVE.SW · CHF
Stock price, earnings
Quote as of Oct 29, 2026, 04:30 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CHF. Historical prices are not a forecast.
EvoNext Holdings S.A.’s quoted price sits in the upper half of its reported 52-week range, 17.88% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
EvoNext Holdings S.A.’s next earnings report is currently expected on Feb 19, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow EvoNext Holdings S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
EvoNext Holdings SA is dedicated to the exploration, creation, and distribution of pioneering ingredients across the nutritional, health, and wellness domains. Founded in 2004, the company's inception is attributed to Alexandra Santana Sørensen, Søren V. S. Nielsen, and Neil Goldsmith. Its corporate headquarters are located in Reinach, Switzerland.
Latest available per-share figures in CHF. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:37 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Mar 9, 2023 |
| -CHF 3.25 |
| CHF 7.40M+2.78% vs estimate |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CHF 39.71+CHF 1.11 (+2.88%)
UBS Group AG’s quoted price sits in the upper half of its reported 52-week range, 11.83% below the high.
$362.28+$6.78 (+1.91%)
Chubb Limited’s quoted price sits in the upper half of its reported 52-week range, 0.99% below the high.
CHF 621.40+CHF 3.00 (+0.49%)
Zurich Insurance Group AG’s quoted price sits in the upper half of its reported 52-week range, 0.96% below the high.
CHF 71.50-CHF 1.90 (-2.59%)
Basilea Pharmaceutica AG’s quoted price sits in the upper half of its reported 52-week range, 5.67% below the high.
CHF 15.60+CHF 0.64 (+4.28%)
Santhera Pharmaceuticals Holding AG’s quoted price sits in the upper half of its reported 52-week range, 17.2% below the high.
CHF 9.13+CHF 0.29 (+3.28%)
Newron Pharmaceuticals S.p.A.’s quoted price sits in the lower half of its reported 52-week range, 71.33% below the high.
CHF 2.99-CHF 0.01 (-0.33%)
Molecular Partners AG’s quoted price sits in the lower half of its reported 52-week range, 24.49% below the high.
CHF 0.02-CHF 0.00 (-0.96%)
Addex Therapeutics Ltd’s quoted price sits in the lower half of its reported 52-week range, 70.14% below the high.
